Apellis Pharmaceuticals, Inc.
APLSNASDAQHealthcare
$41.03
+$0.00(+0.00%)
Market Cap$5.3B
P/E Ratio—
52W High$41.14
52W Low$16.61
Apellis Pharmaceuticals, Inc. (APLS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · APLS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.00B | $0.78B | $0.40B | $0.08B | $0.07B |
| Cost of Revenue | $0.10B | $0.12B | $0.06B | $0.01B | $0.01B |
| Gross Profit | $0.90B | $0.66B | $0.34B | $0.07B | $0.06B |
| Gross Margin %(computed) | 89.81% | 84.93% | 85.25% | 92.53% | 92.19% |
| Operating Expenses | |||||
| R&D Expenses | $0.30B | $0.33B | $0.35B | $0.39B | $0.42B |
| G&A Expenses | $0.00B | $0.42B | $0.50B | $0.28B | $0.18B |
| Total Operating Expenses | $0.85B | $0.83B | $0.86B | $0.66B | $0.60B |
| Operating Income | $0.06B | ($0.16B) | ($0.52B) | ($0.59B) | ($0.54B) |
| Operating Margin %(computed) | 5.52% | -21.11% | -130.39% | -788.38% | -805.67% |
| Interest Income | $0.01B | $0.01B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.04B | $0.04B | $0.03B | $0.03B | $0.01B |
| Income Before Tax | $0.02B | ($0.20B) | ($0.53B) | ($0.65B) | ($0.75B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.02B | ($0.20B) | ($0.53B) | ($0.65B) | ($0.75B) |
| Net Margin %(computed) | 2.23% | -25.32% | -133.29% | -864.70% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.18 | $-1.60 | $-4.45 | $-6.15 | $-8.84 |
| Wtd Avg Shares | 0.13B | 0.12B | 0.12B | 0.11B | 0.08B |
| EBITDA | $0.07B | ($0.15B) | ($0.50B) | ($0.62B) | ($0.73B) |
| EBITDA Margin %(computed) | 6.97% | -19.78% | -124.87% | -818.58% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Apellis Pharmaceuticals, Inc. data
About Apellis Pharmaceuticals, Inc. (APLS) Income Statement
Apellis Pharmaceuticals, Inc. (APLS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, APLS reported revenue of $1.00B, gross profit of $0.90B (gross margin 89.81%), and net income of $0.02B — a net profit margin of 2.23%.
Frequently asked questions
APLS · 4 questionsApellis Pharmaceuticals, Inc. (APLS) reported revenue of $1.00B for 2025, up 28.5% year-over-year.
APLS revenueAPLS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08